Hagop Kantarjian, MD
Medical Oncology · Houston, TXNPI 1316020290
Payments from drug & device makers
Across 303 payments — averaging $331,725 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$77.7M
- Daiichi Sankyo Inc.$9.1M
- AbbVie$6.2M
- Jazz Pharmaceuticals Inc.$6.2M
- Otsuka Pharmaceutical Co., Ltd.$273K
- Janssen Research & Development, LLC$269K
- plus $908K from 21 others
Across 32 payments — averaging $1736.03 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$26K
- Amgen$20K
- Bristol Myers Squibb$4K
- AbbVie$4K
- Novartis$618
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 10 | $77,664,074 |
| Daiichi Sankyo Inc. | 11 | $9,054,408 |
| AbbVie | 66 | $6,187,941 |
| Jazz Pharmaceuticals Inc. | 10 | $6,155,953 |
| Otsuka Pharmaceutical Co., Ltd. | 6 | $273,363 |
| Janssen Research & Development, LLC | 8 | $268,873 |
| Agios Pharmaceuticals, Inc. | 2 | $216,311 |
| Pfizer | 35 | $182,581 |
| Hikma Pharmaceuticals USA | 32 | $118,237 |
| Novartis | 22 | $104,434 |
| Stemline Therapeutics Inc. | 16 | $84,337 |
| Amgen | 28 | $59,783 |
| Ipsen Biopharmaceuticals, Inc | 15 | $26,854 |
| Bristol Myers Squibb | 2 | $22,875 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $17,269 |
| Sumitomo Pharma America, Inc. | 4 | $16,115 |
| Taiho Oncology, Inc. | 1 | $15,000 |
| AstraZeneca | 7 | $14,496 |
| Janssen Global Services, LLC | 8 | $7,849 |
| Astellas Pharma US Inc | 1 | $4,563 |
| Cycle Pharmaceuticals Inc | 1 | $3,500 |
| Genentech USA, Inc. | 2 | $3,409 |
| Gilead | 1 | $3,020 |
| Rigel Pharmaceuticals, Inc. | 1 | $3,000 |
| Adaptive Biotechnologies Corporation | 1 | $2,500 |
| Servier Pharmaceuticals LLC | 2 | $1,650 |
| Beone Medicines USA, Inc. | 1 | $143 |
How this compares
$100,512,537 in reported general payments places this provider in the 95th percentile of 495 medical oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in Houston
- Timothy YapHouston$56.7M
- Yasir ElaminHouston$41.3M
- David HongHouston$31.6M
- Guillermo Garcia-ManeroHouston$31.6M
- Jason WestinHouston$30.8M
- Lucia MasarovaHouston$29.7M
- Jordi Rodon AhnertHouston$28.1M
- Sarina Piha PaulHouston$26M
- Jenny ChangHouston$17.8M
- Hun LeeHouston$15.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.